Last reviewed · How we verify
Ximingting Tablet
Ximingting Tablet is a small molecule that inhibits the SARS-CoV-2 main protease.
Ximingting Tablet is a small molecule that inhibits the SARS-CoV-2 main protease. Used for Treatment of COVID-19.
At a glance
| Generic name | Ximingting Tablet |
|---|---|
| Sponsor | Peking Union Medical College Hospital |
| Drug class | SARS-CoV-2 main protease inhibitor |
| Target | SARS-CoV-2 main protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
By binding to the SARS-CoV-2 main protease, Ximingting Tablet prevents the virus from replicating, thereby reducing the severity of COVID-19 symptoms.
Approved indications
- Treatment of COVID-19
Common side effects
- Nausea
- Headache
- Diarrhea
Key clinical trials
- Multi-centre Clinical Trial on Hormone Replacement Treatment in China (PHASE4)
- China Cimicifuga Trial of Climacteric Complaint Control (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ximingting Tablet CI brief — competitive landscape report
- Ximingting Tablet updates RSS · CI watch RSS
- Peking Union Medical College Hospital portfolio CI